Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 11:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Losartan 100 mg Clear all
Completed Phase 2Phase 3 Interventional

AVE7688 in Patients With Mild to Moderate Blood Pressure

NCT00284128
View directory record Official record
Conditions
Hypertension
Interventions
AVE7688, Losartan-potassium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

NCT01149486
View directory record Official record
Conditions
Healthy
Interventions
Losartan potassium/Hydrochlorothiazide, Hyzaar®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2011 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Not applicable Interventional Results available

A Controlled Trial of Losartan in Posttraumatic Stress Disorder

NCT02709018
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
losartan, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
La Jolla, California • Washington D.C., District of Columbia • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed Conditions

NCT01216878
View directory record Official record
Conditions
Hypertension
Interventions
losartan potassium
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Early Phase 1 Interventional

Losartan for Sickle Cell Kidney Disease

NCT01989078
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Losartan
Drug
Lead sponsor
Emory University
Other
Eligibility
9 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

NCT02235909
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg)
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 7, 2026, 11:12 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

Olmesartan Comparison to Losartan in Hypertensive Subjects

NCT00949884
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Placebo, losartan potassium
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • Harbor City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Renoprotection in Early Diabetic Nephropathy in Pima Indians

NCT00340678
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Losartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Oct 7, 2026, 11:12 PM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Hypertension, Vascular Stiffness, Aging
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 7, 2026, 11:12 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis

NCT02416102
View directory record Official record
Conditions
COPD, Chronic Bronchitis
Interventions
Losartan 50 mg, Losartan 100 mg
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 7, 2026, 11:12 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV

NCT02560805
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
Procedure · Behavioral · Drug + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Early Phase 1 Interventional

Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240

NCT03435939
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Losartan
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted Conditions

NCT01102478
View directory record Official record
Conditions
Hypertension
Interventions
losartan potassium / hydrochlorothiazide
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

NCT05012631
View directory record Official record
Conditions
Sickle Cell Disease, Diffuse Myocardial Fibrosis
Interventions
Losartan
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 7, 2026, 11:12 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

NCT06693960
View directory record Official record
Conditions
Interaction
Interventions
Oregano, Drug cocktail
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 3 Interventional Results available

Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

NCT00723801
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Atenolol, Losartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 7, 2026, 11:12 PM EDT
Completed Phase 2 Interventional Results available

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

NCT03295734
View directory record Official record
Conditions
Hypertension, Aging, Sedentary Lifestyle
Interventions
Aerobic exercise, Perindopril, Losartan, HCTZ
Behavioral · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 7, 2026, 11:12 PM EDT